Novartis AG's Long-Suffering Alcon Sees Sales Growth in Q2, Opening Door to Spin-Off IPO
ZURICH (Reuters) - Novartis long-suffering Alcon eye care unit's sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, Chief Executive Joe Jimenez said on Tuesday.
Alcon sales rose 1 percent to $1.5 billion, including intraocular lenses that grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss.
Alcon sales rose 1 percent to $1.5 billion, including intraocular lenses that grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss.